Deposition of aerosolized pentamidine and failure of pneumocystis prophylaxis.
OBJECTIVE
To determine if outcome of Pneumocystis carinii prophylaxis is related to total lung dose of aerosolized pentamidine.


METHODS
AIDS treatment centers at a VA and University Hospital.


METHODS
Fifty-eight HIV-infected patients receiving P carinii prophylaxis with aerosolized pentamidine using a nebulizer (CIS-US AeroTech II) were followed up over a 90-week period. Treatment consisted of 60 to 90 mg every two weeks.


METHODS
In all patients, deposition of pentamidine aerosol was measured using a radioaerosol filter technique. Factors thought to be important in deposition, nebulizer output and breathing pattern were also measured. Six months later, repeated deposition studies were performed in 20 patients. Pentamidine dose to the lung was related to occurrence of P carinii pneumonia and correlated with nebulizer function and breathing parameters. Outcome was assessed in terms of pentamidine deposition and patient characteristics, including demographic, immunologic, physiologic, and medical variables.


RESULTS
Ten patients (17.2 percent) had development of P carinii pneumonia. However, pentamidine deposited in the failures (8.18 +/- 4.74 mg) was no different than deposition in protected patients (6.39 +/- 3.07 mg, p = NS). Most of the variability in deposition was accounted for by variability in nebulizer output (r = 0.919, p less than 0.001). Deposition did not significantly correlate with any of the measured breathing parameters. Serial deposition measurements were not significantly different by paired analysis. The incidence of P carinii pneumonia did not correlate with any measured patient characteristic.


CONCLUSIONS
Failure of aerosolized pentamidine prophylaxis is not related to total lung dose of pentamidine. Other factors such as inadequate microscopic deposition between alveoli, pentamidine clearance, or drug resistance may be important. In HIV-infected patients, interpatient variability in aerosol deposition can be reduced by reducing variability in nebulizer output rather than control of breathing pattern.
Smaldone
G C
GC
Department of Medicine, State University, Stony Brook, NY.
Dickinson
G
G
Marcial
E
E
Young
E
E
Seymour
J
J
D000336:Aerosols; D015658:HIV Infections / Q000150:complications; D006801:Humans; D008168:Lung / Q000378:metabolism; D010419:Pentamidine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000517:prevention & control*; D012307:Risk Factors
D000336:Aerosols; D010419:Pentamidine